Company intelligence / Profile preview

Ganymed Pharmaceuticals

Mainz, Rhineland-Palatinate, Germany

Ownership: Private
Employees: ~100
Development stage: Phase 2

Overview

Lead program IMAB362 was in advanced Phase II testing for gastroesophageal cancer at the time of acquisition. IMAB362 binds to Claudin-18.2, which is expressed in up to 80% of gastroesophageal adenocarcinomas, 60% of pancreatic tumors, and other solid cancers.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (IMABs - Ideal Monoclonal Antibodies)
Industry: Biotech

Drug pipeline

1 asset

IMAB362

Phase 2

Indications: gastric adenocarcinoma and precursor lesions, gastroesophageal junction adenocarcinoma of esophagus (GEJAC), Pancreatic cancer

Beyond the preview

Go deeper on Ganymed Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ganymed Pharmaceuticals.

Explore the full profile